IL4基因变异与肺癌放疗后重度放射性肺炎关联的验证研究
该前瞻性队列研究(NCT02490319)纳入359例接受放疗的肺癌患者,对19个既往发表的放射性肺炎相关SNP进行验证。多因素分析显示,年龄较大、MLD≥15 Gy、V20≥24%与RP≥3级风险升高相关,IMRT与风险降低相关;IL4 rs2243250 CT+TT基因型与RP≥3级风险显著降低相关。
要点
- IL4 rs2243250 CT+TT基因型与RP≥3级风险降低独立相关(HR=0.195)。
- MLD≥15 Gy、V20≥24%及年龄较大与RP≥3级风险升高相关。
- 接受IMRT的患者RP≥3级发生率较低(HR=0.520)。
核心结论
- IL4 rs2243250在本队列中被验证与肺癌放疗后RP≥3级显著相关,可能成为放疗前重度RP的重要预测因子。
研究设计与样本
- 前瞻性队列研究(NCT02490319),纳入359例接受放疗的肺癌患者,采用MassArray和Sanger测序对外周血样本进行基因分型,验证19个2016年前发表的RP相关SNP候选。
主要发现
- 年龄较大者RP≥3级风险升高(HR=2.020,95%CI 1.045-3.906,P=0.037)。
- MLD≥15 Gy者RP≥3级风险升高(HR=2.502,95%CI 1.346-4.652,P=0.004)。
- V20≥24%者RP≥3级风险升高(HR=2.256,95%CI 1.191-4.272,P=0.013)。
- 接受IMRT者RP≥3级发生率降低(HR=0.520,95%CI 0.280-0.963,P=0.037)。
- IL4 rs2243250 CT+TT基因型与RP≥3级风险降低相关(HR=0.195,95%CI 0.090-0.424,P=0.000037,Pc=0.0006)。
关键数值与推荐
- IL4 rs2243250 CT+TT基因型与RP≥3级风险降低相关(HR=0.195,95%CI 0.090-0.424,P=0.000037,Pc=0.0006)。
- MLD≥15 Gy与RP≥3级风险升高相关(HR=2.502,95%CI 1.346-4.652,P=0.004)。
- V20≥24%与RP≥3级风险升高相关(HR=2.256,95%CI 1.191-4.272,P=0.013)。
临床怎么用
- 放疗前可检测IL4 rs2243250基因型,结合MLD、V20及年龄等剂量学与临床因素综合评估重度RP风险。
- 在满足靶区覆盖前提下,优先考虑IMRT以降低RP≥3级风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Recent researches demonstrated that single nucleotide polymorphisms (SNPs) of genes involving inflammation, DNA repair, etc. were associated with risk of radiation pneumonitis (RP). However, these studies were single-centered, from single ethnic origin, without validation from independent cohort studies from other populations. In order to identify clinical valuable SNPs for RP, in this study we selected 19 RP-related SNPs candidates previously published before 2016 for validation in our cohort. MATERIAL AND METHODS: 359 lung cancer patients with radiotherapy were included in our prospective study (NCT02490319). Peripheral blood samples from these patients were genotyped by MassArray and Sanger Sequence method. Multivariate Cox hazard and other analyses were applied to estimate the hazard ratio (HR) and 95% confidence intervals (CIs) of all factors possibly related to the risk of RP. RESULTS: Patients with elder age, MLD ≥15 Gy, V20 ≥24% had higher risk of RP ≥grade 3 compared with their counterparts (HR = 2.020, 95% CI: 1.045-3.906, P = 0.037; HR = 2.502, 95% CI: 1.346-4.652, P = 0.004; HR = 2.256, 95% CI: 1.191-4.272, P = 0.013, respectively). Moreover, patients receiving IMRT were associated with decreased incidence of RP (HR = 0.520, 95% CI: 0.280-0.963, P = 0.037). Importantly, CT + TT genotype of IL4: rs2243250 was strongly related to decreased risk of RP ≥grade 3 (HR = 0.195, 95% CI: 0.090-0.424, P = 0.000037, Pc = 0.0006). CONCLUSION: IL4: rs2243250 was validated to be significantly related to RP of grade ≥3 in our cohort. Our results further emphasized the prevalence and clinical value of IL4: rs2243250 on RP, and may thus be one of the important predictors of severe RP before radiotherapy.
引用
- Tang Y, Yang L, Qin W, et al. Validation study of the association between genetic variant of IL4 and severe radiation pneumonitis in lung cancer patients treated with radiation therapy. Radiother Oncol. 2019. PMID: 31540745. doi:10.1016/j.radonc.2019.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。